Ulipristal Acetate

CHEMBL260538 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
475.6 g/mol
LogP
3.5
Phase
4

Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to progesterone receptors with high affinity, acting as both an agonist and antagonist depending on tissue context, thereby inhibiting ovulation and altering endometrial receptivity. It is approved for emergency contraception within 5 days of unprotected intercourse and for treatment of uterine fibroids and endometriosis. Its antiprogestogenic activity in reproductive tissues also makes it a subject of research in hormone-sensitive breast cancer.

น้ำหนักโมเลกุล

475.6000 g/mol

LogP

3.50

TPSA

63.70 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C

InChI

InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1

Molecular Formula

C30H37NO4

HBD / HBA

- / 5

พันธะที่หมุนได้

5

อะตอมหนัก

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to progesterone receptors with high affinity, acting as both an agonist and antagonist depending on tissue context, thereby inhibiting ovulation and altering endometrial receptivity. It is approved for emergency contraception within 5 days of unprotected intercourse and for treatment of uterine fibroids and endometriosis. Its antiprogestogenic activity in reproductive tissues also makes it a subject of research in hormone-sensitive breast cancer.

Yes, Ulipristal Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL260538. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 130904. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.